Please assess the completion status of the following clinical trial:

Trial Title: S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytologically confirmed small cell lung cancer;~* Systemic chemotherapy that has previously received at least one or more lines regimen, followed by disease progression or recurrence;~* Age 18-75 years,ECOG PS:0-2,Life expectancy of more than 3 months~* participants had at least one measurable target lesion by RECIST1.1~* The main organ function meets the following criteria:absolute value of neutrophils ≥ 1.5 × 109 / L, platelets ≥80 × 109 / L, hemoglobin ≥ 80 g / L;total bilirubin ≤ 1.5 times the upper limit of normal value, aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times the upper limit of normal value (if liver metastasis, ≤ upper limit of normal value 5 times), serum creatinine ≤ 1.5 times the upper limit of normal;~* Patients should participate in the study voluntarily and sign informed consent~Exclusion Criteria:~* Patients who have been used anti-angiogenesis inhibitors,such as (such as sunitinib,bevacizumab,endostar et al.~* Subjects with symptomatic brain metastases;~* Patients whose primary lesion with active bleeding within 4 months~* Hypertension, which is uncontrolled by the drug, is defined as: systolic blood pressure ≥ 160 mmHg, or diastolic blood pressure ≥ 100 mmHg~* Patients with active or unable to control serious infections~* Patients who are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- S1/Anlotinib (Type: EXPERIMENTAL): Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).